Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/rivaroxaban-with-or-without-aspirin-for-the-secondary-prevention-of-HQnnj07XJp
References (62)
-
C. Cannon, Deepak Bhatt, J. Oldgren, G. Lip, S. Ellis, Takeshi Kimura, M. Maeng, B. Merkely, U. Zeymer, S. Gropper, M. Nordaby, E. Kleine, Ruth Harper, Jenny Manassie, J. Januzzi, J. Berg, G. Steg, S. Hohnloser (2017)
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial FibrillationThe New England Journal of Medicine, 377
-
S. Nissen, S. Nicholls, I. Sipahi, P. Libby, J. Raichlen, C. Ballantyne, J. Davignon, R. Erbel, J. Tardif, P. Schoenhagen, T. Crowe (2006)
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.JAMA, 295 13
-
Marc Bonaca, P. Nault, R. Giugliano, A. Keech, A. Pineda, Estella Kanevsky, J. Kuder, S. Murphy, J. Jukema, B. Lewis, L. Tokgozoglu, R. Somaratne, P. Sever, T. Pedersen, M. Sabatine (2017)
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)Circulation, 137
-
MA Hussain, M Al-Omran, M Mamdani, N Eisenberg, A Premji, L Saldanha (2016)
Efficacy of a guideline-recommended risk-reduction program to improve cardiovascular and limb outcomes in patients with peripheral arterial diseaseJAMA Surg., 151
-
P. Libby (2013)
Mechanisms of acute coronary syndromes and their implications for therapy.The New England journal of medicine, 368 21
-
B. Zinman, C. Wanner, J. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, M. Mattheus, T. Devins, O. Johansen, H. Woerle, U. Broedl, S. Inzucchi (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.The New England journal of medicine, 373 22
-
J. Herlitz, J. Holm, M. Peterson, B. Karlson, Maria Evander, L. Erhardt (2004)
Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study.European heart journal, 25 3
-
M. Hurlen, M. Abdelnoor, Pål Smith, J. Erikssen, H. Arnesen (2002)
Warfarin, aspirin, or both after myocardial infarction.The New England journal of medicine, 347 13
-
R. Yeh, Eric Secemsky, D. Kereiakes, Sharon-Lise Normand, A. Gershlick, David Cohen, J. Spertus, P. Steg, D. Cutlip, M. Rinaldi, E. Camenzind, W. Wijns, Patricia Apruzzese, Yang Song, J. Massaro, L. Mauri (2016)
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.JAMA, 315 16
-
M. Sabatine, David Morrow, R. Giugliano, Paul Burton, S. Murphy, C. Mccabe, C. Gibson, E. Braunwald (2005)
Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary SyndromesCirculation, 111
-
M. Krantz, S. Kaul (2013)
The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51).Journal of the American College of Cardiology, 62 9
-
Z. Ademi, E. Zomer, A. Tonkin, D. Liew (2018)
Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective.International journal of cardiology, 270
-
C. Cannon, M. Blazing, R. Giugliano, A. McCagg, Jennifer White, P. Théroux, H. Darius, B. Lewis, T. Ophuis, J. Jukema, G. Ferrari, W. Rużyłło, Paul Lucca, K. Im, E. Bohula, C. Reist, S. Wiviott, A. Tershakovec, T. Musliner, E. Braunwald, R. Califf (2015)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.The New England journal of medicine, 372 25
-
D. Clement (1996)
A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 348
-
W. Dewilde, T. Oirbans, F. Verheugt, J. Kelder, B. Smet, J. Herrman, T. Adriaenssens, M. Vrolix, A. Heestermans, M. Vis, Jan Tijsen, A. Hof, J. Berg (2013)
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trialThe Lancet, 381
-
S. Connolly, J. Eikelboom, J. Bosch, G. Dagenais, L. Dyal, F. Lanas, K. Metsarinne, M. O’Donnell, A. Dans, J. Ha, A. Parkhomenko, Á. Avezum, E. Lonn, L. Lisheng, C. Torp-Pedersen, P. Widimsky, A. Maggioni, C. Félix, K. Keltai, M. Hori, K. Yusoff, T. Guzik, Deepak Bhatt, K. Branch, N. Bruns, S. Berkowitz, Sonia Anand, J. Varigos, K. Fox, S. Yusuf, Jorgelina Sala, L. Cartasegna, M. Vico, M. Hominal, E. Hasbani, A. Caccavo, C. Zaidman, Daniel Vogel, A. Hrabar, P. Schygiel, C. Cuneo, H. Lúquez, I. Mackinnon, R. Guerrero, J. Costabel, Ines Bartolacci, O. Montaña, M. Barbieri, O. Vilamajó, R. Duran, L. Schiavi, M. Garrido, A. Ingaramo, Anselmo Bordonava, María Pelagagge, Leonardo Novaretto, J. Gennero, Luz Saggia, M. Alvarez, N. Vita, S. Macin, R. Dran, M. Cardona, Luis Guzman, Rodolfo Sarjanovich, J. Cuadrado, S. Nani, Marcos Bruno, C. Chacón, L. Maffei, D. Grinfeld, N. Vensentini, C. Majul, H. Luciardi, Patricia Colaso, F. Pacora, P. Heuvel, P. Verhamme, B. Ector, P. Debonnaire, P. Borne, J. Leroy, H. Schroe, P. Vranckx, I. Elegeert, E. Hoffer, K. Dujardin, Clarisse Brasil, D. Précoma, J. Abrantes, E. Manenti, Gilmar Reis, J. Saraiva, L. Maia, M. Hernandes, Paulo Rossi, Fabio Santos, S. Zimmermann, R. Rech, E. Abib, P. Leães, R. Botelho, Ó. Dutra, W. Souza, M. Braile, N. Izukawa, J. Nicolau, L. Tanajura, C. Júnior, C. Minelli, L. Nasi, L. Oliveira, M. Cantarelli, R. Tytus, S. Pandey, E. Lonn, J. Cha, S. Vizel, M. Babapulle, A. Lamy, K. Saunders, J. Berlingieri, B. Kiaii, R. Bhargava, Pravinsagar Mehta, Laurie Hill, David Fell, Andy Lam, F. Al-Qoofi, Craig Brown, R. Petrella, J. Ricci, A. Glanz, N. Noiseux, K. Bainey, F. Merali, M. Heffernan, A. Siega, G. Dagenais, F. Dagenais, Steeve Brulotte, M. Nguyen, M. Hartleib, Randolph Guzman, R. Bourgeois, D. Rupka, Y. Khaykin, G. Gosselin, T. Huynh, C. Pilon, Jean Campeau, Francis Pichette, Ariel Díaz, J. Johnston, Pravin Shukle, Gregory Hirsch, Paula Rheault, W. Czarnecki, A. Roy, S. Nawaz, S. Fremes, D. Shukla, Gabriel Jano, J. Cobos, R. Corbalán, M. Medina, Leonardo Nahuelpan, C. Raffo, Luis Pérez, S. Potthoff, B. Stockins, P. Sepúlveda, Christian Pincetti, M. Véjar, H. Tian, Wu Xuesi, Ke Yuannan, Kaiying Jia, Pengfei Yin, Zhaohui Wang, Yu Litian, Wu Shulin, WU Zongqui, Shao-wen Liu, X. Bai, Yang Zheng, Ping Yang, Yunhui Yang, Jiwei Zhang, G. Junbo, X. Chen, L. Junxia, Huang Taohong, Ruiyan Zhang, Zhe Zheng, Xin Chen, L. Tao, L. Jianping, Weijian Huang, Fu Guosheng, Li Chunjian, Yu-ying Dong, Chunsheng Wang, Xin-min Zhou, Ye Kong, A. Sotomayor, J. Mendoza, Henry Castillo, M. Urina, G. Aroca, Maritza Pérez, D. Salazar, G. Vallejo, Manzur-Jattin Fernando, H. García, Luis Garcia, E. Arcos, Juan Gomez, Francisco Millan, Fredy Dada, B. Vesga, Gustavo Silgado, E. Zidkova, J. Lubanda, M. Kaletová, Radim Kryza, Gabriel Marcinek, M. Richter, J. Špinar, J. Matuška, M. Tesák, Z. Motovska, M. Branny, J. Malý, M. Malý, M. Wiendl, L. Caisová, J. Slaby, P. Vojtíšek, J. Pirk, L. Špinarová, M. Benesová, J. Čanádyová, M. Homza, Jindrich Florian, R. Polášek, Z. Coufal, V. Skalníková, R. Brát, M. Brtko, P. Janský, J. Lindner, P. Marcián, Z. Straka, M. Třetina, Y. Duarte, F. Long, M. Sánchez, José López, C. Perugachi, R. Mármol, Freddy Trujillo, P. Terán, J. Tuomilehto, H. Tuomilehto, M. Tuominen, I. Kantola, G. Steg, V. Aboyans, F. Leclercq, E. Ferrari, F. Boccara, E. Messas, P. Mismetti, M. Sevestre, G. Cayla, P. Motreff, S. Stoerk, H. Duengen, C. Stellbrink, Osman Guerocak, C. Kadel, R. Braun-Dullaeus, M. Jeserich, C. Opitz, H. Voehringer, K. Appel, Bernhard Winkelmann, T. Dorsel, S. Nikol, H. Darius, J. Ranft, S. Schellong, W. Jungmair, P. Davierwala, M. Vorpahl, L. Bajnok, Z. László, E. Noori, G. Veress, A. Vértes, A. Zsáry, E. Kis, L. Koranyi, J. Bakai, Z. Boda, F. Poor, Z. Járai, V. Kemény, J. Barton, B. Mcadam, A. Murphy, P. Crean, N. Mahon, R. Curtin, B. Macneill, S. Dinneen, M. Halabi, R. Zimlichman,, D. Zeltser, Y. Turgeman, E. Klainman, B. Lewis, A. Katz, S. Atar, E. Nikolsky, S. Bosi, M. Naldi, P. Faggiano, Debora Robba, L. Mos, G. Sinagra, F. Cosmi, L. Visconti, DE Carmine, G. Pasquale, M. Biase, S. Mandorla, M. Bernardinangeli, G. Piccinni, M. Gulizia, M. Galvani, F. Venturi, G. Morocutti, M. Baldin, C. Olivieri, G. Perna, V. Cirrincione, Takayasu Kanno, H. Daida, Y. Ozaki, N. Miyamoto, S. Higashiue, Hiroshi Domae, S. Hosokawa, Hiroo Kobayashi, T. Kuramochi, K. Fujii, K. Mizutomi, K. Saku, K. Kimura, Y. Higuchi, M. Abe, Haruhito Okuda, T. Noda, T. Mita, A. Hirayama, H. Onaka, M. Inoko, M. Hirokami, M. Okubo, Yutaka Akatsuka, M. Imamaki, H. Kamiya, M. Manita, T. Himi, H. Ueno, Yuji Hisamatsu, J. Ako, Yasuhiro Nishino, H. Kawakami, Yutaka Yamada, Y. Koretsune, Takahisa Yamada, Tetsuro Yoshida, H. Shimomura, N. Kinoshita, A. Takahashi, K. Yusoff, W. Ahmad, M. Hassan, S. Kasim, A. Rahim, D. Zamrin, M. Machida, Y. Higashino, Noriaki Utsu, A. Nakano, Shigeru Nakamura, T. Hashimoto, K. Ando, T. Sakamoto, F. Prins, D. Lok, J. Milhous, E. Viergever, F. Willems, H. Swart, M. Alings, Robert Breedveld, K. Vries, Roger Borgh, F. Oei, Stieneke ZOET-NUGTEREN, H. Kragten, J. Herrman, P. Bergen, M. Gosselink, E. Hoekstra, E. Zegers, E. Ronner, F. Hartog, Gerard Bartels, P. Nierop, C. Zwaan, Jacob Eck, E. Gorselen, B. Groenemeijer, P. Hoogslag, M. Groot, A. Loyola, D. Sulit, Nannette Rey, M. Abola, D. Morales, E. Palomares, M. Abat, G. Rogelio, Philip Chua, Joselyn Pilar, J. Alcaraz, G. Ebo, L. Tirador, J. Cruz, Johannes Añonuevo, Arthur Pitargue, M. Janion, T. Guzik, G. Gajos, M. Zabówka, A. Rynkiewicz, M. Broncel, A. Szuba, D. Czarnecka, P. Maga, I. Strazhesko, Y. Vasyuk, Z. Sizova, Y. Pozdnyakov, O. Barbarash, M. Voevoda, T. Poponina, A. Repin, I. Osipova, A. Efremushkina, N. Novikova, O. Averkov, D. Zateyshchikov, A. Vertkin, A. Ausheva, P. Commerford, Saadiya Seedat, L. Zyl, Janine Engelbrecht, E. Makotoko, C. Pretorius, Zaidi Mohamed, A. Horak, T. Mabin, E. Klug, J. Bae, Cheolho Kim, C. Kim, Dong-Soo Kim, Yong Kim, S. Joo, H. Jong‐Won, C. Park, J. Kim, Young-Kwon Kim, C. Jarnert, T. Mooe, M. Dellborg, I. Torstensson, P. Albertsson, L. Johansson, F. Al-Khalili, H. Almroth, T. Andersson, E. Pantev (2017)
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.Lancet, 391 10117
-
B. Neal, V. Perkovic, K. Mahaffey, D. Zeeuw, G. Fulcher, N. Erondu, Wayne Shaw, G. Law, Mehul Desai, D. Matthews (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesThe New England Journal of Medicine, 377
-
Deepak Bhatt, K. Fox, W. Hacke, P. Berger, H. Black, W. Boden, P. Cacoub, E. Cohen, M. Creager, J. Easton, M. Flather, S. Haffner, C. Hamm, G. Hankey, S. Johnston, K. Mak, J. Mas, G. Montalescot, T. Pearson, P. Steg, S. Steinhubl, M. Weber, D. Brennan, Liz Fabry-Ribaudo, J. Booth, E. Topol (2006)
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.The New England journal of medicine, 354 16
-
S. Subherwal, M. Patel, L. Køber, E. Peterson, Deepak Bhatt, G. Gislason, A. Olsen, W. Jones, C. Torp-Pedersen, E. Fosbøl (2015)
Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide studyEuropean Journal of Preventive Cardiology, 22
-
Stephen Nicholls, E. Tuzcu, I. Sipahi, Adam Grasso, P. Schoenhagen, T. Hu, K. Wolski, T. Crowe, M. Desai, Stanley Hazen, Samir Kapadia, S. Nissen (2007)
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.JAMA, 297 5
-
J. Eikelboom, S. Mehta, Sonia Anand, C. Xie, K. Fox, S. Yusuf (2006)
Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary SyndromesCirculation, 114
-
S. Schulman, C. Kearon (2005)
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 3
-
N. Mackman (2004)
Role of tissue factor in hemostasis, thrombosis, and vascular development.Arteriosclerosis, thrombosis, and vascular biology, 24 6
-
S. Wiviott, E. Braunwald, C. Mccabe, G. Montalescot, W. Rużyłło, S. Gottlieb, F. Neumann, D. Ardissino, Stefano Servi, S. Murphy, J. Riesmeyer, G. Weerakkody, M. Gibson, E. Antman (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes.The New England journal of medicine, 357 20
-
K. Fiedler, M. Maeng, J. Mehilli, Stefanie Schulz-Schüpke, R. Byrne, D. Sibbing, P. Hoppmann, S. Schneider, M. Fusaro, I. Ott, S. Kristensen, T. Ibrahim, S. Massberg, H. Schunkert, K. Laugwitz, A. Kastrati, N. Sarafoff (2015)
Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial.Journal of the American College of Cardiology, 65 16
-
S. Marso, S. Bain, A. Consoli, F. Eliaschewitz, E. Jódar, Lawrence Leiter, I. Lingvay, J. Rosenstock, J. Seufert, M. Warren, V. Woo, O. Hansen, A. Holst, Jonas Pettersson, T. Vilsbøll (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.The New England journal of medicine, 375 19
-
L. Fiore, M. Ezekowitz, M. Brophy, David Lu, J. Sacco, P. Peduzzi (2002)
Department of Veterans Affairs Cooperative Studies Program Clinical Trial Comparing Combined Warfarin and Aspirin With Aspirin Alone in Survivors of Acute Myocardial Infarction: Primary Results of the CHAMP StudyCirculation: Journal of the American Heart Association, 105
-
S. Nicholls, R. Puri, T. Anderson, C. Ballantyne, L. Cho, J. Kastelein, W. Koenig, R. Somaratne, H. Kassahun, Jingyuan Yang, S. Wasserman, R. Scott, I. Ungi, J. Podolec, A. Ophuis, J. Cornel, Marilyn Borgman, D. Brennan, S. Nissen (2016)
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.JAMA, 316 22
-
WR Hiatt, FG Fowkes, G Heizer, JS Berger, I Baumgartner, P Held (2017)
Ticagrelor versus Clopidogrel in symptomatic peripheral artery diseaseN Engl J Med, 376
-
RF Es, JJ Jonker, FW Verheugt, JW Deckers, DE Grobbee (2002)
Antithrombotics in the Secondary Preventionof Events in Coronary Thrombosis-2 Research G. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trialLancet., 360
-
K. Ray, H. Ginsberg, M. Davidson, R. Pordy, L. Bessac, P. Minini, R. Eckel, C. Cannon (2016)
Reductions in Atherogenic Lipids and Major Cardiovascular EventsCirculation, 134
-
R. Es, J. Jonker, F. Verheugt, J. Deckers, D. Grobbee (2002)
Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trialThe Lancet, 360
-
Coumadin Investigators (1997)
Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarctionThe Lancet, 350
-
M. Sabatine, R. Giugliano, A. Keech, Narimon Honarpour, S. Wiviott, S. Murphy, J. Kuder, Huei Wang, Thomas Liu, S. Wasserman, P. Sever, T. Pedersen (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseThe New England Journal of Medicine, 376
-
J. Mega, E. Braunwald, S. Wiviott, J. Bassand, Deepak Bhatt, C. Bode, P. Burton, Marc Cohen, N. Cook-Bruns, K. Fox, S. Goto, S. Murphy, A. Plotnikov, D. Schneider, Xiang Sun, F. Verheugt, C. Gibson (2012)
Rivaroxaban in patients with a recent acute coronary syndrome.The New England journal of medicine, 366 1
-
M. Brouwer, P. Bergh, W. Aengevaeren, G. Veen, H. Luijten, D. Hertzberger, A. Boven, Ralf Vromans, G. Uijen, F. Verheugt (2002)
Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction: Results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 TrialCirculation: Journal of the American Heart Association, 106
-
R. Nieuwlaat, A. Capucci, A. Camm, S. Olsson, D. Andresen, D. Davies, S. Cobbe, G. Breithardt, J. Heuzey, M. Prins, S. Lévy, H. Crijns (2005)
Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation.European heart journal, 26 22
-
J. Eikelboom, S. Connolly, J. Bosch, G. Dagenais, R. Hart, O. Shestakovska, R. Diaz, M. Alings, E. Lonn, Sonia Anand, P. Widimsky, M. Hori, Á. Avezum, L. Piegas, K. Branch, J. Probstfield, Deepak Bhatt, Jun Zhu, Yan Liang, A. Maggioni, P. López-Jaramillo, M. O’Donnell, Ajay Kakkar, K. Fox, A. Parkhomenko, G. Ertl, S. Störk, M. Keltai, L. Rydén, N. Pogosova, A. Dans, F. Lanas, P. Commerford, C. Torp-Pedersen, T. Guzik, P. Verhamme, D. Vinereanu, Jae‐Hyung Kim, A. Tonkin, B. Lewis, C. Félix, K. Yusoff, G. Steg, K. Metsarinne, N. Bruns, F. Misselwitz, E. Chen, D. Leong, S. Yusuf (2017)
Rivaroxaban with or without Aspirin in Stable Cardiovascular DiseaseThe New England Journal of Medicine, 377
-
M. Patel, K. Mahaffey, Jyotsna Garg, Guohua Pan, D. Singer, W. Hacke, G. Breithardt, J. Halperin, G. Hankey, J. Piccini, R. Becker, C. Nessel, J. Paolini, S. Berkowitz, K. Fox, R. Califf (2011)
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.The New England journal of medicine, 365 10
-
E. Peterson (2016)
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.The New England journal of medicine, 375 25
-
V. Fuster, L. Badimón, J. Badimón, J. Chesebro (1992)
The pathogenesis of coronary artery disease and the acute coronary syndromes (2).The New England journal of medicine, 326 5
-
M. Hussain, M. Al-Omran, M. Mamdani (2016)
Efficacy of a Guideline-Recommended Risk-Reduction Program to Improve Cardiovascular and Limb Outcomes in Patients With Peripheral Arterial Disease.Journal of vascular surgery, 64 2
-
J. Oldgren, L. Wallentin, J. Alexander, S. James, Birgitta Jönelid, G. Steg, J. Sundström (2013)
New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysisEuropean Heart Journal, 34
-
Sonia Anand, J. Bosch, J. Eikelboom, S. Connolly, Compass Investigators (2018)
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.Lancet, 391 10117
-
L. Mauri, D. Kereiakes, Robert Yeh, Priscilla Driscoll-Shempp, D. Cutlip, P. Steg, Sharon-Lise Normand, Eugene, Braunwald, S. Wiviott, David Cohen, David Holmes, Mitchell Krucoff, J. Hermiller, H. Dauerman, I. Daniel, Simon, D. Kandzari, Kirk Garratt, David Lee, Thomas Pow, Peter Lee, Michael Rinaldi, Joseph Massaro (2014)
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.The New England journal of medicine, 371 23
-
Marc Bonaca, J. Gutierrez, M. Creager, B. Scirica, J. Olin, S. Murphy, E. Braunwald, D. Morrow (2016)
Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis–Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50)Circulation, 133
-
W. Hiatt, G. Fowkes, G. Heizer, J. Berger, I. Baumgartner, P. Held, B. Katona, K. Mahaffey, L. Norgren, Schuyler Jones, J. Blomster, Marcus Millegård, C. Reist, M. Patel (2017)
Ticagrelor Versus Clopidogrel in Symptomatic Peripheral Artery DiseaseJournal of Vascular Surgery, 65
-
Deepak Bhatt, K. Eagle, E. Ohman, A. Hirsch, S. Goto, E. Mahoney, P. Wilson, M. Alberts, R. D'Agostino, C. Liau, J. Mas, J. Röther, Sidney Smith, G. Salette, C. Contant, J. Massaro, P. Steg (2010)
Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis.JAMA, 304 12
-
Stefanie Schulz-Schüpke, R. Byrne, J. Berg, F. Neumann, Yaling Han, T. Adriaenssens, R. Tölg, M. Seyfarth, M. Maeng, B. Zrenner, C. Jacobshagen, H. Mudra, E. Hodenberg, J. Wöhrle, D. Angiolillo, Barbara Merzljak, Nonglag Rifatov, S. Kufner, T. Morath, Antonia Feuchtenberger, T. Ibrahim, P. Janssen, C. Valina, Yi Li, W. Desmet, M. Abdel-Wahab, K. Tiroch, C. Hengstenberg, I. Bernlochner, M. Fischer, H. Schunkert, K. Laugwitz, A. Schömig, J. Mehilli, A. Kastrati (2015)
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.European heart journal, 36 20
-
L. Wallentin, R. Becker, A. Budaj, C. Cannon, H. Emanuelsson, C. Held, J. Horrow, S. Husted, S. James, H. Katus, K. Mahaffey, B. Scirica, A. Skene, P. Steg, R. Storey, R. Harrington, A. Freij, M. Thorsén (2009)
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.The New England journal of medicine, 361 11
-
KK Ray, HN Ginsberg, MH Davidson, R Pordy, L Bessac, P Minini (2016)
Reductions in atherogenic lipids and major cardiovascular events: a pooled analysis of 10 ODYSSEY trials comparing alirocumab with controlCirculation, 134
-
R. Bauersachs, S. Berkowitz, B. Brenner, H. Buller, H. Décousus, A. Gallus, A. Lensing, F. Misselwitz, M. Prins, G. Raskob, A. Segers, P. Verhamme, P. Wells, G. Agnelli, H. Bounameaux, A. Cohen, B. Davidson, F. Piovella, S. Schellong (2010)
Oral rivaroxaban for symptomatic venous thromboembolism.The New England journal of medicine, 363 26
-
N. Begum, S. Stephens, O. Schoeman, A. Fraschke, B. Kirsch, J. Briere, F. Verheugt, B. Hout (2015)
Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in SwedenCardiology and Therapy, 4
-
Anonymous (1997)
Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) InvestigatorsLancet., 350
-
S. Marso, Gilbert Daniels, K. Brown-Frandsen, Peter Kristensen, Johannes Mann, Michael Nauck, Steven Nissen, Stuart Pocock, Neil Poulter, Lasse Ravn, William Steinberg, M. Stockner, B. Zinman, R. Bergenstal, J. Buse (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.The New England journal of medicine, 375 4
-
R. Puri, S. Nissen, C. Ballantyne, P. Barter, M. Chapman, R. Erbel, P. Libby, J. Raichlen, J. John, K. Wolski, K. Uno, Y. Kataoka, S. Nicholls (2013)
Factors underlying regression of coronary atheroma with potent statin therapy.European heart journal, 34 24
-
J. Alexander, R. Becker, Deepak Bhatt, F. Cools, F. Crea, M. Dellborg, K. Fox, S. Goodman, R. Harrington, K. Huber, S. Husted, B. Lewis, J. López-Sendón, Puneet Mohan, G. Montalescot, M. Ruda, W. Rużyłło, F. Verheugt, L. Wallentin (2009)
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) TrialCirculation, 119
-
Marc Bonaca, Deepak Bhatt, Marc Cohen, P. Steg, R. Storey, E. Jensen, G. Magnani, S. Bansilal, M. Fish, K. Im, O. Bengtsson, T. Ophuis, A. Budaj, P. Théroux, M. Ruda, C. Hamm, S. Goto, J. Špinar, J. Nicolau, R. Kiss, S. Murphy, S. Wiviott, P. Held, E. Braunwald, M. Sabatine (2015)
Long-term use of ticagrelor in patients with prior myocardial infarction.The New England journal of medicine, 372 19
-
Magnus Ohman, M. Roe, G. Steg, S. James, T. Povsic, Jennifer White, F. Rockhold, Alexei Plotnikov, H. Mundl, J. Strony, Xiang Sun, S. Husted, M. Tendera, G. Montalescot, Cecilia Bahit, D. Ardissino, H. Bueno, M. Claeys, J. Nicolau, J. Cornel, S. Goto, R. Kiss, Ü. Güray, Duk‐Woo Park, C. Bode, R. Welsh, Michael Gibson, Janssen Research, AG DevelopmentBayer, MB ProfEMOhman, James, Neurociencias Oroño, Rosario Santa, Argentina Fe, Divisione di, Cardiologia, Policlinico San, Matteo, Italy Pavia, Ardissino, Spanish, Men Women (2017)
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trialThe Lancet, 389
-
J. Oldgren, A. Budaj, C. Granger, Y. Khder, Juliet Roberts, A. Siegbahn, J. Tijssen, F. Werf, L. Wallentin (2011)
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.European heart journal, 32 22
-
J. Mega, E. Braunwald, Satishkumar Mohanavelu, P. Burton, R. Poulter, F. Misselwitz, V. Hricák, E. Barnathan, P. Bordes, A. Witkowski, V. Markov, L. Oppenheimer, C. Gibson (2009)
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trialThe Lancet, 374
-
M. Dennis (1996)
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering CommitteeThe Lancet, 348
- Publisher
- Springer Journals
- Copyright
- Copyright © 2019 by Springer Nature Switzerland AG
- Subject
- Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
- ISSN
- 1175-3277
- eISSN
- 1179-187X
- DOI
- 10.1007/s40256-018-00322-4
- Publisher site
- See Article on Publisher Site
Abstract
The COMPASS trial compared the impact of the selective direct factor Xa inhibitor, rivaroxaban, as monotherapy or in combination with aspirin on major adverse cardiovascular events (MACE) in patients with stable atherosclerotic disease. Patients treated with rivaroxaban 2.5 mg twice daily in combination with aspirin experienced fewer cardiovascular events but more bleeding complications than those who received aspirin monotherapy. In contrast, a higher dose of rivaroxaban (5 mg twice daily) and aspirin produced no clinical benefit and continued to be associated with greater bleeding rates than aspirin. Examining this study in the context of other trials of anticoagulant therapy in atherosclerotic vascular disease, this review attempts to place the role of very low-dose rivaroxaban in clinical context and highlights areas for future research.
Journal
American Journal of Cardiovascular Drugs – Springer Journals
Published: Jan 25, 2019